Previous data showed deep MRD-negative responses among patients with pretreated relapsed/refractory multiple myeloma who received cevostamab.
Prerna Mewawalla, MD
Advertisement
Articles by Prerna Mewawalla, MD
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
CRS, neurotoxicities, and infections are the most common AEs associated with BCMA- and GPRC5D-directed therapies in patients with multiple myeloma.
Advertisement
Latest Updated Articles
Managing Toxicities in BCMA/GPRC5D-Directed Therapies in Multiple MyelomaSeptember 26th 2025
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
2
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
5